[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-participants\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-participants":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,137,0,25,[9,46,74,101,126,154,182,214,241,261,281,304,330,348,367,392,414,438,458,480,508,526,548,574,585],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053223","phase-1-a-study-to-investigate-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-azd4954-in-healthy-adult-participants-with-or-without-elevated-lipoprotein-a-lpa-levels-and-participants-with-dyslipidemia-100053223",false,"NCT06980428","A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia","A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4954 Following Single and Multiple Ascending Dose Administration to Healthy Participants With or Without Elevated Lp(a) Levels, and Participants With Dyslipidemia","Inclusion Criteria:\n\nAll Parts:\n\n* Participants with plasminogen level (concentration) within normal range at the Screening Visit.\n* All females must have a negative pregnancy test at the Screening Visit and on admission to the study site.\n* Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception.\n* Females of non-childbearing potential must be confirmed at the Screening Visit.\n* Sexually active fertile male participants with partners of childbearing potential must adhere to the study specific contraception methods from the time of first administration of study intervention until 3 months after the study Follow-up Visit.\n\nParts A and B (Healthy Participants):\n\n* Male and female participants aged 18 to 65 years with suitable veins for cannulation or repeated venipuncture.\n* Have a body mass index (BMI) between 18 and 35 kg\u002Fm² inclusive.\n* For Japanese and Chinese participants (Parts A and B):\n\n  1. A Japanese participant is defined as having both parents and 4 grandparents who are ethnically Japanese. This includes second and third generation Japanese whose parents or grandparents are living in a country other than Japan.\n  2. A Chinese participant is defined as having both parents and 4 grandparents who are ethnically Chinese. This includes second and third generation Chinese whose parents or grandparents are living in a country other than China.\n\n     Part B (Healthy Participants):\n* Participants must have elevated Lp(a) ≥ 30 mg\u002FdL at the Screening Visit.\n\nPart B (Participants with Dyslipidemia):\n\n* Male and female participants aged 18 to 70 years with suitable veins for cannulation or repeated venipuncture.\n* Have a BMI \\> 18 kg\u002Fm².\n* Participants must have elevated Lp(a) ≥ 70 mg\u002FdL at the Screening Visit.\n* Participants with a fasting LDL-C ≥ 70 mg\u002FdL and \\\u003C 190 mg\u002FL at the Screening Visit.\n* Participants should be receiving moderate or high-intensity statin therapy for ≥ 2 months prior to the Screening Visit, according to the American College of Cardiology\u002FAmerican Heart Association guidelines on blood cholesterol management.\n* Participants with documented coronary artery disease, stroke, or peripheral artery disease or at moderate or high risk for an atherosclerotic cardiovascular disease event.\n* There should be no planned medication or dose change during study participation.\n\nExclusion Criteria:\n\nAll Parts:\n\n* History of any clinically important disease or disorder.\n* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Any clinically important illness, medical\u002Fsurgical procedure, or trauma within 4 weeks of the first administration of study intervention.\n* Participants with known bleeding or coagulation disorders.\n* Participants who have an elevated high-sensitivity C-reactive protein (\\> 3 mg\u002FL) or have a prothrombin time\u002Finternational normalized ratio (PT\u002FINR) or activated partial thromboplastin time (aPTT) \\> 1.25 times × upper limit normal (ULN).\n* Any clinically important abnormalities in hematology, coagulation, clinical chemistry, urinalysis, abnormal vital signs or abnormal laboratory values.\n* Any positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV) or human immunodeficiency virus (HIV).\n* Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead electrocardiogram (ECG) at Screening.\n* Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of study intervention.\n\nParts A and B (Healthy Participants):\n\n* Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol\u002Facetaminophen), herbal remedies, intake of \\> 3 × daily recommended levels of vitamins and minerals during the 2 weeks prior to the first administration of study intervention or longer if the medication has a long half-life.\n* Current smokers or those who have smoked or used nicotine products.\n\nPart B (Participants with Dyslipidemia):\n\n* Acute ischemic cardiovascular event in the last 12 months prior to randomization.\n* Poorly controlled diabetes.\n* Previous administration of Lp(a) inhibitor.\n* Have uncontrolled hypertension.\n* Abnormal vital heart rate.","ALL","18 Years","70 Years",{"count":21,"type":22},136,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4954 in healthy participants with or without elevated Lipoprotein(a) (Lp\\[a\\]) levels and participants with dyslipidemia.",[28,29],"Healthy Participants","Dyslipidemia",[31,32],"Lipoprotein(a)","Low-density lipoprotein cholesterol (LDL-C)","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2025-05-27",{"date":41,"type":22},"2026-12-04",{"name":43,"class":44},"AstraZeneca","INDUSTRY",6,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100053624","the-increasing-mindfulness-engagement-project-100053624","NCT07170202","The Increasing Mindfulness Engagement Project","Translating Behavioral Economics Strategies to Culturally Tailor a Mobile Health Mindfulness Intervention to Reduce Risky Drinking Behaviors in Emerging Adult College Student Students","TIMEProject","Inclusion Criteria:\n\n18-29 years old First-generation college student Undergraduate college student Living in the United States Meet criteria for binge drinking (5 drinks in about 2 hours) or heavy drinking (more than 14 drinks per week).",true,"29 Years",{"count":57,"type":22},40,[59],"NA","The goal of this clinical trial is to examine the feasibility and acceptability of different types of text messages and a integrated gaming app to increase engagement in a mindfulness mobile health application.\n\n1. Does receiving text messages increase engagement in a mindfulness app?\n2. Does an integrated gaming app increase engagement in a mindfulness app?\n\nResearchers will examine whether participants engage more in a mindfulness mobile health application if they receive text messages and if they engage in additional gaming app on their smartphone. Participants will:\n\n1. Use a mindfulness and gaming mobile health application for 28-days.\n2. Complete a pre-study survey, post-study survey, follow-up interview, and 3-month follow-up survey in addition to daily brief surveys.",[28,62,63],"Feasibility Studies","Acceptability","2026-07-09",{"date":36,"type":37},{"date":67,"type":37},"2025-09-30",{"date":69,"type":22},"2027-08-06",{"name":71,"class":72},"Florida State University","OTHER",1,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100634864","phase-1-comparing-the-extent-to-which-two-evolocumab-drug-products-are-made-available-in-the-body-after-a-single-subcutaneous-dose-100634864","NCT07545226","Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.","An Open-Label, Phase 1, Single Dose, Randomized, Parallel-group Study to Evaluate the Relative Bioavailability of Two Evolocumab (AMG 145) Drug Products","Inclusion Criteria:\n\n1. Male or female, of any race, between 18 and 60 years of age, inclusive.\n\n   a. Females must not be pregnant or lactating.\n2. Body mass index (BMI) between 18.0 and 32.0 kg\u002Fm\\^2 inclusive.\n3. LDL-C level ≥ 70 mg\u002FdL (1.8 mmol\u002FL) and ≤ 190 mg\u002FdL (4.9 mmol\u002FL) at screening.\n\nExclusion Criteria:\n\n1. History or evidence of any clinically significant disorder, condition, or disease that in the opinion of the investigator (or designee) would pose a risk to participant safety or interfere with the trial evaluation, procedures, or completion.\n2. History or current signs or symptoms of cardiovascular disease.\n3. History or evidence of clinically significant arrhythmia.\n4. History of hypersensitivity, intolerance, or allergy to evolocumab or its ingredients or other biological drugs.\n5. Uncontrolled hyperthyroidism or hypothyroidism.\n6. Current use or prior use of over-the-counter or other prescription medications, herbal medicines, vitamins, and supplements within 30 days or 5 half-lives prior to check-in.\n7. Participation in another investigational device or drug trial within the past 30 days or 5 half-lives prior to check-in.\n8. Have previously completed or withdrawn from this trial or any other trial investigating evolocumab, any other product directed against PCSK9, or have previously received evolocumab or PCSK9 inhibitor.","60 Years",{"count":83,"type":22},400,[25],"The primary objective of this trial is to evaluate the pharmacokinetics (PK) of two evolocumab drug products in healthy participants.",[28],[88,89,90],"Evolocumab","AMG 145","Pharmacokinetics","2026-06-30",{"date":93,"type":37},"2026-07-01",{"date":95,"type":37},"2026-04-21",{"date":97,"type":22},"2026-09-08",{"name":99,"class":44},"Amgen",5,{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100615259","phase-1-a-study-to-investigate-safety-tolerability-and-pharmacokinetics-of-azd3974-in-healthy-participants-100615259","NCT07290283","A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants","A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD3974 After Single and Multiple Ascending Dosing to Healthy Participants","Inclusion Criteria:\n\n* Healthy male and female (of non-childbearing potential) participants with suitable veins for cannulation or repeated venipuncture at the Screening Visit.\n* All females must have a negative pregnancy test. Females of non-childbearing potential must be confirmed via post-menopausal status or documentation of irreversible surgical sterilization at the Screening Visit.\n* Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods.\n* Have a body mass index between 18 and 32 kg\u002Fm2 inclusive and weigh at least 50 kg at Screening.\n* For healthy Japanese cohorts (Part A2 and Part B2): healthy male and female participants are to be Japanese (eg, natives of Japan or Japan Americans), defined as having both parents and 4 grandparents who are Japanese. This includes second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan.\n* For healthy Chinese cohort (Part A3): healthy male and female Chinese participants for whom both parents and 4 grandparents are Chinese. This includes second and third generation participants of Chinese descent whose parents or grandparents are living in a country other than China.\n\nExclusion Criteria:\n\n* History of any clinically important disease or disorder which, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.\n* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Any clinically important illness, medical\u002Fsurgical procedure, or trauma within 4 weeks of the first administration of study intervention.\n* Any abnormal laboratory values, vital signs, or any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.\n* Any positive result on Screening for serum hepatitis B and C viruses and human immunodeficiency virus.\n* Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12 lead electrocardiography at Screening and\u002For admission to the Clinical Unit .\n* Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.\n* Positive screen for drugs of abuse, or alcohol, or cotinine.\n* History of severe allergy\u002Fhypersensitivity or ongoing clinically important allergy\u002Fhypersensitivity.\n* Participants who have previously received AZD3974.","55 Years",{"count":110,"type":22},176,[25],"The purpose of this study is to assess the safety and tolerability of AZD3974 and characterize the pharmacokinetics (PK) of AZD3974 following oral administration to healthy participants, including participants of Japanese and Chinese descent.",[28],[115,116,90,117,118],"Single ascending dose","Multiple ascending dose","Impact of food","First-in-human",{"date":93,"type":37},{"date":121,"type":37},"2025-12-10",{"date":123,"type":22},"2026-10-21",{"name":43,"class":44},2,{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100542946","phase-1-a-study-of-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-sr604-in-two-participants-groups-part-a-healthy-participants-and-part-b-participants-with-hemophilia-a-or-hemophilia-b-or-factor-vii-deficiency-100542946","NCT06349473","A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)","A Phase 1 Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Healthy Participants (Part A) and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SR604 in Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency (Part B)","Key Inclusion Criteria:\n\nPart A:\n\n* Male participants aged 18 to 55 years, inclusive.\n* Body mass index between 18 and 30 kilograms per meter square (kg\u002Fm\\^2), inclusive, and weighs greater than or equal to (\\>=) 50 kilograms (kg), less than or equal to (\\\u003C=) 90 kg.\n* No clinically significant findings on medical examination, including physical examination, 12-lead electrocardiogram, and clinical laboratory tests.\n* Sexually active men must commit to use an effective method of birth control while taking the study intervention and for 90 days after the dose of study intervention.\n\nPart B:\n\n* Male and female participants (only female participants with congenital FVII deficiency) aged 18 to 60 years, inclusive.\n* Participants must have one of the following bleeding disorders: Severe hemophilia A (\\\u003C1% Factor VIII \\[FVIII\\]); or Severe and\u002For moderately severe Hemophilia B (≤ 2% Factor IX \\[FIX\\]); or Severe FVII deficiency (\\\u003C10% FVII activity). Participants with severe FVII deficiency must satisfy with either of following criteria:\n\n  1. Participants with history of \\>2 bleeding events in the last 12 months require on-demand treatment with recombinant factor VIIa (rFVIIa) or plasma-derived FVII concentrates (pd-FVII) or fresh frozen plasma (FFP) for bleeding control.\n  2. Participants on prophylaxis treatment with rFVIIa or pd-FVII or FFP regardless of bleeding history.\n* Participants with Hemophilia A or Hemophilia B must satisfy either of the following criteria:\n\n  1. Participants not on prophylaxis must have a documented ABR of 6 in 12 months before screening.\n  2. Participants on prophylaxis must have a documented ABR of ≥ 2 in 12 months before screening.\n  3. Intolerant to current treatment regimen.\n* Medical records documenting a minimum of 2 years of bleeding event history.\n* Willing to undergo a weaning period from prior treatment or prophylaxis for Hemophilia A or Hemophilia B or FVII deficiency.\n* Sexually active men must commit to use an effective method of birth control while taking the study intervention and for 90 days after the dose of SR604.\n* Women of childbearing potential must have a negative pregnancy test at the Screening Visit and agree to follow the contraception guidance during the intervention period and for at least 90 days after the last dose of SR604.\n\nKey Exclusion Criteria:\n\nPart A:\n\n* Participant has clinically significant history or evidence of cardiovascular, respiratory (including all chronic lung diseases), hepatic, renal, gastrointestinal, endocrine, neurological, immunological, bleeding, or psychiatric disorder(s).\n* Participant has a mean pulse less than (\\\u003C) 40 or greater than (\\>) 90 beats per minute (bpm), mean systolic blod pressure (BP) \\\u003C 90 millimeter of mercury (mmHg) or \\> 140 mmHg, or mean diastolic BP \\\u003C 50 mmHg or \\> 90 mmHg at the screening visit.\n* Participant has a mean corrected QT corrected for heart rate by Fridericia's formula (QTcF) of \\> 450 msec at the Screening Visit.\n* Participant has had injury, trauma, and\u002For major surgery within 3 months before Screening, or is planned to undergo surgery during the study.\n* Participant has received vaccination within 14 days before the dose of study intervention or has a vaccination planned during the study.\n* History of one or more of the following in participants and\u002For family members:\n\n  1. Factor V (FV) Leiden mutation.\n  2. Activated protein C (APC) resistant.\n  3. Protein C (PC) or protein S (PS) deficiency.\n  4. Prothrombin 20210 mutation;\n  5. Antithrombin III (ATIII) deficiency.\n* History of clinically significant intracranial hemorrhage, pneumonia, chronic liver disease, liver or kidney transplants, or malignant diseases.\n* Any medical condition (eg, diabetes, obesity.) which, in the Investigator's opinion, could compromise participant safety, interfere with study intervention metabolism, or put the study outcome at undue risk. Any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the participant or could prevent, limit or confound protocol-specified assessments.\n* Participants with a history of all types of thrombosis, including any arterial and\u002For venous thrombosis, superficial thrombophlebitis, or embolism. Additionally, participants with a history of thrombotic microangiopathy, stroke, and transient ischemic attack (TIA), or abnormal findings in any prior laboratory thrombophilia evaluation will be excluded.\n\nPart B:\n\n* Participants with a history of all types of thrombosis, including any arterial and\u002For venous thrombosis, superficial thrombophlebitis, or embolism. Additionally, participants with a history of thrombotic microangiopathy, stroke, and TIA, or abnormal findings in any prior laboratory thrombophilia evaluation will be excluded.\n* History of one or more of the following in participants and\u002For family members:\n\n  1. FV Leiden mutation.\n  2. APC resistant.\n  3. PC or PS deficiency.\n  4. Prothrombin 20210 mutation.\n  5. ATIII deficiency.\n* Impaired cardiac function or clinically significant cardiac disease, including any of the following:\n\n  1. Clinically significant and\u002For uncontrolled heart disease such as congestive heart failure requiring treatment (New York Heart Association Grade \\>=2), left ventricular ejection fraction \\\u003C 50% as determined by multiple gated acquisition or echocardiogram, or clinically significant arrhythmia.\n  2. QTcF \\> 450 ms ECG or congenital Long QT Syndrome at the Screening Visit.\n  3. Acute myocardial infarction or unstable angina pectoris \\\u003C 3 months prior to study entry.\n* Uncontrolled hypertension (systolic BP \\> 150 mmHg and diastolic BP \\> 100 mmHg), a history of hypertension crisis, or a history of hypertensive encephalopathy.\n* Participant with the following laboratory abnormalities:\n\n  1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 1.5 × upper limit of normal (ULN);\n  2. Total bilirubin ˃3.0 × ULN and direct bilirubin ˃1.5 × ULN (unless due to Gilbert's syndrome).\n* Calculated creatinine clearance ˂ 60 mL\u002Fmin using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula at the Screening Visit.\n* Participant has positive test result for human immunodeficiency virus (HIV) antibody.\n\n  1. If participants test positive for hepatitis B core antibody (HBcAb), additional tests including hepatitis B surface antibody, hepatitis B surface antigen (HBsAg), and hepatitis B viral deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) will be conducted to determine if there is an active infection. Participants with active infection will be excluded from the study.\n  2. Participants who test positive for hepatitis C virus antibody will be required to have a negative result for hepatitis C viral ribonucleic acid (RNA) PCR before enrollment. Individuals with positive results for hepatitis C PCR will be excluded from the study.\n* Chronic liver disease (Child-Pugh class C hepatic impairment), or history of liver or kidney transplants.\n* Injury, trauma, and\u002For major surgery (mediastinoscopy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery), major dental procedures (extractions, etc.) within 4 weeks of the first dose of SR604 or planned surgery during the study.\n* Active infection requiring systemic antibiotic or antiviral therapy or in a sepsis condition within 14 days prior to the first dose of SR604.\n* Any medical condition (eg, diabetes, obesity) which, in the Investigator's opinion, could compromise participant safety, interfere with SR604 metabolism, or put the study outcome at undue risk.\n* Female participants who are pregnant or are currently breastfeeding or planning to become pregnant while enrolled in this study or within 90 days after the last dose of SR604.",{"count":134,"type":22},31,[25],"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII) deficiency, with or without inhibitors (Part B).",[28,138,139,140],"Hemophilia A","Hemophilia B","Factor VII Deficiency",[115,116,142,143,144],"Factor IX","Factor VIII","Factor VII",{"date":146,"type":37},"2026-07-02",{"date":148,"type":37},"2024-05-10",{"date":150,"type":22},"2026-09-28",{"name":152,"class":44},"Equilibra Bioscience LLC",10,{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":73},"100643998","combined-regulatory-effects-of-40-hz-etns-and-multisensory-stimulation-on-brain-networks-100643998","NCT07668167","Combined Regulatory Effects of 40 Hz eTNS and Multisensory Stimulation on Brain Networks","A Study on the Enhancing Effects of 40 Hz Combined Trigeminal-Sensory Stimulation on Working Memory","Inclusion Criteria:\n\n* Healthy adults aged ≥18 years old.\n* Normal or corrected-to-normal vision and hearing (essential for 40Hz visual and auditory stimulation).\n* Right-handedness.\n* Willing to participate in the study and capable of providing written informed consent.\n\nExclusion Criteria:\n\n* Personal or family history of epilepsy or seizures (crucial safety criteria for 40Hz flicker and electrical stimulation).\n* History of any neurological or psychiatric disorders.\n* Presence of metallic implants in the head, cardiac pacemakers, or other implanted electronic medical devices.\n* Skin lesions, infections, or hypersensitivity at the eTNS stimulation site (maxillary branch of the trigeminal nerve).\n* Current use of psychoactive medications or substances that may significantly alter EEG signals or brain state dynamics.\n* Pregnant or lactating individuals.\n* Poor sleep quality or irregular sleep-wake cycles prior to the experiment.",{"count":162,"type":22},30,[59],"The purpose of this study is to investigate the independent and interactive effects of 40Hz auditory, visual, and external trigeminal nerve stimulation (eTNS) on brain state dynamics and functional connectivity. While 40Hz visual and auditory sensory stimulation have been explored for potential cognitive and therapeutic benefits, the underlying mechanisms on large-scale brain networks and the potential effects of combining multiple modalities remain unclear.\n\nThis study aims to determine whether multimodal co-stimulation genuinely compounds network-level effects or if targeted dual-pairings are more efficient for brain network reorganization. In this within-subject study, 23 participants will receive all eight possible combinations of 40Hz auditory, visual, and eTNS (targeting the maxillary branch) in a randomized order. Each stimulation condition will last for 5 minutes, separated by 1-minute inter-stimulus intervals. Continuous electroencephalography (EEG) will be recorded throughout the procedures to evaluate brain responses. The collected EEG data will be analyzed using microstate analysis, functional connectivity analysis, and graph-theoretic network analysis. Ultimately, the study seeks to understand how these non-invasive stimulation techniques, independently and together, drive large-scale network reorganization and optimize the balance between local specialization and global integration in the brain.",[28],[167,168,169,170,171,172,173],"External trigeminal nerve stimulation (eTNS)","40Hz stimulation","Multimodal neuromodulation","Brain network reorganization","Network topology","Functional connectivity","EEG microstates","2026-06-28",{"date":93,"type":37},{"date":177,"type":37},"2026-06-16",{"date":179,"type":22},"2026-06-23",{"name":181,"class":72},"Xidian University",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":198,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":73},"100641361","phase-1-a-study-to-learn-how-different-amounts-of-the-study-medicine-called-pf-08103402-are-tolerated-and-act-in-the-body-in-healthy-adults-or-adults-with-mild-to-moderate-asthma-100641361","NCT07660731","A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma","A PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, RELATIVE BIOAVAILABILITY, FOOD EFFECT, METABOLISM & EXCRETION, AND DRUG-DRUG INTERACTION POTENTIAL OF PF-08103402 IN HEALTHY ADULTS AND\u002FOR ADULTS WITH MILD TO MODERATE ASTHMA","Key Inclusion criteria (Parts A, B, C, D and F):\n\n1. Are males or females who can no longer have children,\n2. Are 18 to 65 years old,\n3. Have a body mass index (BMI) of 16 to 32 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds).\n\nFor Part A (Optional group or cohort 3: Japanese participants only):\n\n1. A total body weight of more than 45 kg (100 pounds).\n2. Have 4 biological Japanese grandparents who were born in Japan.\n\nFor Part E only:\n\nAdults with a documented doctor's-diagnosis history of asthma for at least 12 months before entering the study.\n\n1\\. Have a body mass index (BMI) of 16 to 35 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds).\n\nKey Exclusion criteria\n\n1. Evidence or history of clinically significant medical conditions.\n2. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb).\n3. History of alcohol abuse or binge drinking and\u002For any other illicit drug use or dependence within 6 months of Screening.\n4. Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study.\n5. Any history of parasitic infection requiring treatment within 28 days prior to screening.\n6. Positive tuberculosis infection test result.\n7. Part C only: Evidence or history of conditions interfering with the ability to taste.\n8. Part D only: History of irregular bowel movements.\n9. Part E only: Evidence of lung disease(s) other than asthma.\n10. Part E only: Asthma exacerbation within 3 months prior to screening.\n11. Part F only: History of acute narrow-angle glaucoma, untreated open-angle glaucoma, sleep apnea, respiratory insufficiency, myasthenia gravis or adverse reaction to midazolam or other benzodiazepines.","65 Years",{"count":191,"type":22},139,[25],"The purpose of this study is to learn about the safety of a new study medicine called PF-08103402 in healthy adults (do not have disease) and or in adults with mild-to-moderate asthma. This is the first time the study medicine is being given to people.\n\nFor Parts A, B, C, D and F, the study is seeking participants who:\n\n* Are healthy (do not have disease) males or females who can no longer have children,\n* Are 18 to 65 years old,\n* Have a body mass index (BMI) of 16 to 32 kilograms per meter squared and a body weight of more than 50 kilograms (110 pounds). Body mass index is a way to measure body fat by using a person's height and weight\n\nFor Part A (optional group or cohort 3: Japanese participants only):\n\n* A body weight of more than 45 kilograms (100 pounds).\n* Have 4 biological Japanese grandparents who were born in Japan.\n\nFor Part E only:\n\n* Adults with a documented history of asthma (confirmed by a doctor) for at least 12 months before entering the study.\n* Have a body mass index (BMI) of 16 to 35 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds).\n\nThe study has six parts: Part A, Part B, Part C, Part D, Part E and Part F. The study medicine will be taken as a suspension or tablet by mouth 1 time a day (except in Parts B and E where it will be taken 1 time a day for 14 days) at the study clinic. The study will help understand:\n\n* how the body processes the study medicine in healthy participants (Parts A and B),\n* how much of the study medicine gets into the bloodstream and if food affects the amount of study medicine in the blood in healthy participants (Part C),\n* how the study medicine is broken down and leaves the body in healthy participants (Optional Part D),\n* how the study medicine is processed in adults with mild-to-moderate asthma (Optional Part E),\n* if taking the study medicine together with another medicine affects how each medicine is processed by the body in healthy participants (Optional Part F).\n\nParticipants will take part in the study for about 10 weeks (Parts A and F), 12 weeks (Part B), 9 weeks (Parts C and D), and 16 weeks (Part E).\n\nDuring this time, they will have 2 study visits at the study clinic and up to 28 overnight stays (Part A), 18 overnight stays (Parts B and E), 10 overnight stays (Part C), 11 overnight stays (Part D), and 16 overnight stays (Part F). The study team will also call participants 1 time over the phone at the end of the study to assess how they are doing.\n\nStudy measurements will be taken by body examination, monitoring side effects, blood and urine tests, heart tests (ECG), vital signs (blood pressure and pulse), questionnaires (Parts C and E), stool samples (Part D only), and breathing tests (Part E only).",[195,196,28,197],"Healthy Volunteer Study","Healthy Adults","Asthma",[199,200,201,202,203,204],"Human","Randomized","Metabolism","Excretion","Drug-Drug Interaction","Food effect","2026-06-24",{"date":207,"type":37},"2026-06-29",{"date":209,"type":37},"2026-06-17",{"date":211,"type":22},"2027-06-18",{"name":213,"class":44},"Pfizer",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":54,"sex":221,"minAge":18,"maxAge":108,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":224,"briefSummary":225,"conditions":226,"keywords":227,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":240},"100634818","phase-1-a-phase-1-study-of-navlimetostat-tablet-formulations-100634818","NCT07544628","A Phase 1 Study of Navlimetostat Tablet Formulations","A Phase 1, Open-label, Randomized, 2-Treatment, 2-Period, Crossover Study to Assess the Bioequivalence of Navlimetostat Wet-Granulation Tablet Versus the Dry-Granulation Tablet Formulation in Healthy Adult Female (as Assigned at Birth) Participants Who Are Individuals Not of Childbearing Potential","Inclusion Criteria:\n\n* Participants must be healthy adult INOCBP female with no clinically significant findings on medical history, PE, VS, 12-lead ECGs, or clinical laboratory determinations, as assessed by the investigator.\n* Participants must have BMI of 18.0 to 35.0 kg\u002Fm2.\n* Participants must have adequate laboratory test results for renal and hepatic function, as assessed by the investigator, defined as eGFR ≥ 90 mL\u002Fmin\u002F1.73m2 using the CKD-EPI equation (screening only), and total bilirubin, ALP, GGT, AST, ALT ≤ 1.5 × ULN.\n\nExclusion Criteria:\n\n* Participant must not have any significant acute or chronic medical illness (in the assessment of the investigator).\n* Participant must not have current or recent GI disease: Any gastrointestinal disease within 3 months of study intervention administration that could possibly affect drug absorption, distribution, metabolism, and excretion (eg, bariatric procedure, history of pancreatitis, uncontrolled nausea or vomiting) in the opinion of the investigator.\n* Other protocol defined inclusion\u002Fexclusion criteria applies.","FEMALE",{"count":223,"type":22},64,[25],"This study aims to compare the PK of Navlimetostat after administration of a wet-granulation tablet versus the dry-granulation tablet formulation in healthy adult female",[28],[228,229,230,231,232],"Healthy adult female","Individuals not of childbearing potential","Open label study","Clinical Research Unit","Phase 1",{"date":205,"type":37},{"date":235,"type":37},"2026-04-27",{"date":237,"type":22},"2026-10-15",{"name":239,"class":44},"Bristol-Myers Squibb",4,{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":73},"100595693","phase-1-a-first-in-human-study-to-evaluate-safety-tolerability-and-pharmacokinetics-of-single-and-multiple-oral-doses-of-debio-1453p-in-healthy-adults-100595693","NCT07035769","A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults","A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Debio 1453P in Healthy Adults","Inclusion Criteria\n\n1. Signed and dated written informed consent obtained before undertaking any trial-specific procedures.\n2. Be within the age range of 18 to 55 years, inclusive, at the time of screening.\n3. Have a body mass index (BMI) ≥18.5 and ≤30.0 kg\u002Fm\\^2.\n\nExclusion criteria\n\n1. History and\u002For physical examination evidence of any clinically significant disease or disorder, such as cardiovascular, pulmonary, renal, hepatic, neurological, gastrointestinal, endocrine, immunological, psychiatric or mental disease or disorder, or mental or legal incapacitation, which, in the opinion of the Investigator, may either put the participant at risk for taking part in the trial, influence the results of the trial, influence the participant's ability to take part in the trial.\n2. Any medication (including vaccines, over the counter (OTC) and\u002For prescription medication, dietary supplements, nutraceuticals, vitamins and\u002For herbal supplements, and hormonal replacement therapy for postmenopausal participants) for 2 weeks or 5 half-lives of the drug, whichever is longer, prior to first administration of trial drug (except occasional paracetamol (maximum dose of 2 g\u002Fday and maximum of 10 g\u002F2 weeks).\n3. History of chronic drug or alcohol abuse (defined as an average intake of more than 21 units of alcohol per week for males and 14 for females. 1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits) in the last 2 years.",{"count":249,"type":22},88,[25],"The main purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of Debio 1453P compared to placebo across different dose levels in healthy adults after single and repeated oral dosing.",[28],"2026-06-22",{"date":179,"type":37},{"date":256,"type":37},"2025-06-18",{"date":258,"type":22},"2026-11",{"name":260,"class":44},"Debiopharm International SA",{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":189,"enrollmentInfo":268,"targetDuration":4,"studyType":23,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":273,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":277,"leadSponsor":279,"locationsCount":4},"100644354","phase-1-a-first-in-human-study-of-aro-033-in-adult-participants-100644354","NCT07662096","A First-In-Human Study of ARO-033 in Adult Participants","A First-In-Human Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ARO-033 in Adult Participants","Key Inclusion Criteria:\n\n* Adults who are not pregnant, not breastfeeding, and do not plan to become pregnant (or impregnate their partners) during the study and for at least 90 days following the end of the study.\n* Body mass index (BMI) between 18.0 and 35.0 kilograms (kg)\u002Fsquare meter (m\\^2), inclusive.\n* No abnormal finding of clinical relevance at the Screening evaluation that in the opinion of the Investigator could adversely impact participant's safety during the study or adversely impact study results.\n\nKey Exclusion Criteria:\n\n* Human immunodeficiency virus (HIV) infection, as shown by the presence of anti-HIV antibody (seropositive).\n* Seropositive for hepatitis B virus (HBV) (hepatitis B surface antigen positive at screening) or hepatitis C virus (HCV) (HCV antibody positive with reflex confirmation using HCV RNA amplification at Screening). Cured HCV (positive antibody test without detectable HCV RNA) is permitted if HCV RNA has been negative for at least 2 years.\n* Uncontrolled hypertension (resting systolic blood pressure ≥160 millimeters of mercury \\[mmHg\\] or diastolic blood pressure ≥95 mmHg, confirmed by repeat measurement, at Screening).\n* Evidence of clinically significant immunocompromising condition (for example, primary immunodeficiency syndrome, aplastic anemia, known or suspected complement factor deficiency, or any other condition resulting in significantly impaired immune response as evidenced by recurrent infections), or recent\u002Fongoing treatment with immunosuppressive agents.\n* History of major surgery within 90 days of Screening.\n* Use of an investigational agent or device within 30 days or 5 half-lives (whichever is longer) prior to dosing or current participation in an investigational study. Participants recently participating in studies involving investigational agents with prolonged therapeutic effect (such as ribonucleic acid interference \\[RNAi\\] therapeutics, cell or gene therapies) should be discussed with the Medical Monitor.\n* Any medical condition or clinically significant laboratory abnormality at Screening that in the opinion of the Investigator should exclude the participant from participation, preclude safe and successful completion of the study, or confound study results.\n\nNote: Other protocol-defined inclusion and exclusion criteria may apply.",{"count":269,"type":22},42,[25],"This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-033 compared to placebo in adult normal healthy volunteers (NHVs).",[28],"NOT_YET_RECRUITING","2026-06-18",{"date":179,"type":37},{"date":253,"type":22},{"date":278,"type":22},"2027-07-18",{"name":280,"class":44},"Arrowhead Pharmaceuticals",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":288,"targetDuration":4,"studyType":23,"phases":290,"briefSummary":291,"conditions":292,"keywords":293,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":73},"100642026","phase-1-a-bioequivalence-study-between-two-casdatifan-tablet-strengths-and-food-effect-study-of-casdatifan-in-healthy-adult-participants-100642026","NCT07641881","A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants","A Phase 1, Open-Label, Randomized, Single-Dose, Three-Treatment, Three-Period, Six-Sequence Crossover Pharmacokinetic Study to Evaluate the Bioequivalence of Two Casdatifan (AB521) Tablet Strengths and Food Effect in Healthy Adult Participants","Inclusion Criteria:\n\n* Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting.\n* BMI ≥ 18.0 and ≤ 32.0 kg\u002Fm2 and body weight ≥ 45 kg at the screening visit.\n* Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, standard vital signs, and ECGs, as deemed by the PI or designee.\n* Able to swallow multiple tablets.\n* Has adequate peripheral venous access.\n\nExclusion Criteria:\n\n* Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.\n* History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.\n* History of asthma or chronic obstructive pulmonary disease (including childhood), clinically significant food allergies or anaphylaxis, as deemed by PI or designee.\n* Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of asymptomatic gallstones).\n* Seizure (excluding simple febrile seizure), epilepsy, severe head injury, multiple sclerosis, or other known neurological conditions which the PI or designee considers to be clinically significant.\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria may apply",{"count":289,"type":22},24,[25],"The purpose of this study is to compare the single-dose pharmacokinetics (PK) of casdatifan 100 mg versus four 25 mg tablets under fasting conditions in healthy adult participants, and to evaluate the effect of food on the single-dose PK of casdatifan 100 mg administered as four 25 mg tablets in healthy adult participants.",[28],[294,295,296,90],"Casdatifan","AB521","HIF-2α",{"date":209,"type":37},{"date":299,"type":37},"2026-05-29",{"date":301,"type":22},"2026-07",{"name":303,"class":44},"Arcus Biosciences, Inc.",{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":311,"targetDuration":4,"studyType":23,"phases":313,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":73},"100642379","phase-1-a-phase-i-cross-over-study-comparing-the-relative-bioavailability-of-laroprovstat-plus-ezetimibe-fixed-combination-drug-products-versus-their-single-therapy-products-in-healthy-adults-100642379","NCT07622433","A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults","A Phase I, Randomized, Open-label, 4-period, 4-treatment, Single-dose, Cross-over Study to Assess the Relative Bioavailability of Laroprovstat\u002FEzetimibe Fixed Combination Drug Products to the Single Therapy Products in Healthy Adults","Inclusion Criteria:\n\n* Healthy male and female participants aged 18 to 55 years at the time of signing consent.\n* All females must have a negative pregnancy test at the Screening Visit and on admission to the study site.\n* Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception.\n* Have a Body mass index (BMI) between 18 and 30 kg\u002Fm2 inclusive and weigh at least 50 kg.\n\nExclusion Criteria:\n\n* History of any clinically important disease or disorder.\n* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* History of severe allergy\u002Fhypersensitivity or ongoing clinically important allergy\u002Fhypersensitivity to drugs with a similar chemical structure or class to laroprovstat or ezetimibe.\n* Treatment with any lipid lowering therapy or laroprovstat within the 3 months prior to the Screening Visit.\n* Treatment with drugs for reduction or inhibition of Proprotein convertase subtilisin\u002Fkexin type 9 (PCSK9) within the last 12 months prior to the Screening Visit or inclisiran at any time.",{"count":312,"type":22},18,[25],"The purpose of this study is to assess how well laroprovstat and ezetimibe combined in a single tablet to be taken by mouth works and what the body does to the drug (pharmacokinetics) compared with laroprovstat and ezetimibe individual tablets to be taken by mouth (relative bioavailability) as well as to see if there is any effect of eating compared to fasting (food effect) in healthy adults.",[28],[317,318,90,319,320,29,321,204,322],"Fixed Combination Drug Products","Bioavailability","Cross-over study","Hyperlipidemia","Relative bioavailability","Oral Formulations","2026-06-15",{"date":177,"type":37},{"date":326,"type":37},"2026-06-10",{"date":328,"type":22},"2026-09-07",{"name":43,"class":44},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":54,"sex":221,"minAge":18,"maxAge":108,"enrollmentInfo":337,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":73},"100634392","phase-1-evaluate-the-effect-of-vimseltinib-on-pharmacokinetics-of-combined-oral-contraceptive-ethinyl-estradiollevonorgestrel-100634392","NCT07539090","Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol\u002FLevonorgestrel)","A Phase 1, Open-label, Fixed-sequence Study to Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol\u002FLevonorgestrel) in Healthy Female Participants","Inclusion Criteria:\n\n1. Participants are in good general health, as required by the protocol and as determined by Principal Investigator.\n2. Body mass index (BMI) from greater than or equal to (≥) 18.5 to less than or equal to ≤ 30 kilogram per square meter (kg\u002Fm\\^2).\n3. Adequate organ function, blood and urine tests, as required by the protocol and as determined by Principal Investigator.\n\nExclusion Criteria:\n\n1. History or presence of clinically significant diseases of the neurological, dermatological, renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal systems or history or presence of clinically significant psychiatric, immunological, endocrine, or metabolic disease as determined by Principal Investigator.\n2. Unwilling or unable to comply with the requirements of the protocol.\n3. Determined by Principal Investigator to be unsuitable to participate in the study for any other reason.",{"count":289,"type":22},[25],"The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol\u002Flevonorgestrel) in healthy female participants. This study will last approximately 35 days.",[28],{"date":209,"type":37},{"date":343,"type":37},"2026-06-05",{"date":345,"type":22},"2026-08",{"name":347,"class":44},"Deciphera Pharmaceuticals, LLC",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":23,"phases":356,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":73},"100609905","cognition-and-ultrasound-100609905","NCT07220655","Cognition and Ultrasound","Inclusion Criteria:\n\n* 18 years of age or older\n* Speak English (as assessed by their ability to read\u002Fanswer survey questions)\n* May be required to score in the appropriate range on self-report measures\n\nExclusion Criteria:\n\n* They have a neurological disorder which may impact their fMRI scan or cause their reaction to LIFU to differ from that of healthy adults.\n* They take any psychoactive medication.\n* They are unable to undergo fMRI scanning due to a contraindication such as claustrophobia, unremovable piercings, pregnancy, the presence of medical devices such as pacemakers, or a movement or sleep disorder.\n* Are pregnant, or may have reason to believe that they are pregnant.\n* They have a diagnosis of a psychiatric condition other than depression or anxiety",{"count":355,"type":22},100,[59],"Our primary goal is to investigate the role of Low-Intensity Focused Ultrasound (LIFU) neuromodulation on deep brain targets, and its potential to improve cognition",[28],"2026-06-12",{"date":323,"type":37},{"date":362,"type":37},"2024-06-01",{"date":364,"type":22},"2028-07-01",{"name":366,"class":72},"University of Minnesota",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":54,"sex":221,"minAge":374,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":23,"phases":378,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":125},"100593992","phase-1-a-study-to-investigate-the-effect-of-azd6234-azd9550-and-a-combination-of-azd9550-and-azd6234-on-pharmacokinetics-of-combined-oral-contraceptive-ethinyl-estradiollevonorgestrel-in-healthy-female-participants-living-with-overweight-or-obesity-100593992","NCT07013643","A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol\u002FLevonorgestrel in Healthy Female Participants Living With Overweight or Obesity","An Open-label, Single-sequence Multiple Cohort Study to Assess the Effect of Multiple Doses of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on the Pharmacokinetics of Single Doses of Combined Oral Contraceptive Ethinyl Estradiol\u002FLevonorgestrel in Healthy Female Participants Living With Overweight or Obesity","Inclusion Criteria:\n\n* All participants must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.\n* Females of childbearing potential must not be lactating and if heterosexually active, must agree to use an approved method of highly effective contraception.\n\n  o Hormonal contraceptives and estrogen-containing hormonal methods of birth control are not permitted due to potential effect and influence on the results using a CoC assessment.\n* Females of non-childbearing potential must be confirmed at the Screening Visit.\n* Have a Body Mass Index (BMI) between 25 and 40 kg\u002Fm2, both inclusive and weigh at least 60 kg for Cohorts 1, 2, and 3 and a BMI of \\> 30 kg\u002Fm2 for Cohort 4.\n\nExclusion Criteria:\n\n* History of any clinically important disease or disorder (gastroparesis, deep vein thrombosis, venous thromboembolism, previous surgery of the upper gastrointestinal tract, cardiovascular disease, neuromuscular or neurogenic disease, severe vitamin D deficiency (cohort 1, cohort 2 and cohort 4), type I or type II diabetes mellitus, glycated hemoglobin (HbA1c) ≥ 6.5% at screening, history of neoplastic disease (cohort 2, cohort 3 and cohort 4), basal calcitonin level \\>50 ng\u002FL (50 pg\u002FL) at screening (cohort 2, cohort 3 and cohort 4), history of acute or chronic pancreatitis or pancreatic amylase or lipase \\>2×ULN at screening (cohort 2, cohort 3 and cohort 4), prior history of cholecystectomy or untreated cholelithiasis and personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN2) (cohort 2, cohort 3 and cohort 4).\n* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Any clinically important illness, medical\u002Fsurgical procedure, or trauma.\n* Any laboratory values with deviations or clinically important abnormalities in clinical chemistry, hematology, or urinalysis.\n* Any positive result on screening for serum Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb) or Human immunodeficiency virus (HIV).\n* Abnormal vital signs.\n* Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12 lead electrocardiogram (ECG), at screening.\n* Current smokers or those who have smoked or used nicotine products.\n* Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.\n* History of severe allergy\u002Fhypersensitivity or ongoing clinically important allergy\u002Fhypersensitivity.\n* Statin treatment within 4 weeks prior to the start of study treatment.\n* Current use of estrogen-containing products.","35 Years","75 Years",{"count":377,"type":22},50,[25],"This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol (EE)\u002Flevonorgestrel (LEVO) in healthy female participants with obesity.",[28],[382,383,384,90,385],"Obesity","Overweight","Oral contraceptives","Drug Interaction",{"date":323,"type":37},{"date":388,"type":37},"2025-06-04",{"date":390,"type":22},"2027-07-09",{"name":43,"class":44},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":399,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":404,"overallStatus":273,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":125},"100589243","phase-1-a-study-to-investigate-the-safety-and-pharmacokinetics-of-single--and-multiple-ascending-doses-of-azd4916-in-healthy-volunteers-100589243","NCT06951880","A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers","A Phase I, Randomized, Single-blind, Placebo-controlled, 2-Part Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD4916 Following Single- and Multiple-ascending-dose Administration to Healthy Adult Volunteers (Including Japanese and Chinese Healthy Volunteers)","Main Inclusion Criteria:\n\n* Healthy male and female participants with suitable veins for cannulation or repeated venipuncture.\n* All females must have negative pregnancy test and females of childbearing potential must not be lactating and must agree to use an approved method of highly effective contraception.\n* Have a Body Mass Index between 18 and 30 kg\u002Fm2 inclusive and weigh at least 45 kg at Screening.\n* Part 2, Japanese participants only: Japanese participants must have been born in Japan, have 2 Japanese biological parents and 4 Japanese grandparents (as confirmed by the interview), and must not have lived outside of Japan for more than 10 years at the time of the Screening Visit.\n* Part 2, Chinese participants only: Chinese participants must have been born in China (including Hong Kong, Macau, and Taiwan), have 2 Chinese biological parents and 4 Chinese grandparents (as confirmed by the interview), and must not have lived outside of China for more than 10 years at the time of the Screening Visit.\n\nMain Exclusion Criteria:\n\n* History of any clinically important disease or disorder which, in the opinion of the Principal Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.\n* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* History of chest irradiation, fibrosis, malignancy, surgical procedure, trauma or liver disease.\n* Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.\n* Evidence of active tuberculosis or Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C virus (HCV) infection.\n* Abnormal vital signs or clinically important abnormalities in rhythm.\n* Current smokers, known or suspected history of alcohol, drug abuse or caffeine intake.\n* History of severe allergy\u002Fhypersensitivity.\n* Plasma donation within 1 month of the Screening Visit or any blood donation\u002Fblood loss \\> 500 mL during the 3 months prior to the Screening Visit.\n* Participants who are vegans or have dietary restrictions.\n* Vulnerable participants, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.",{"count":400,"type":22},160,[25],"The main purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) of AZD4916 in healthy adult participants.",[28],[405,406,90],"Single-ascending dose","Multiple-ascending dose","2026-06-11",{"date":323,"type":37},{"date":410,"type":22},"2026-07-23",{"date":412,"type":22},"2027-10-25",{"name":43,"class":44},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":421,"enrollmentInfo":422,"targetDuration":4,"studyType":23,"phases":424,"briefSummary":425,"conditions":426,"keywords":427,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":431,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":73},"100642467","postprandial-effects-of-fresh-mango-as-a-table-sugar-replacement-in-high-sugar-breakfasts-100642467","NCT07650058","Postprandial Effects of Fresh Mango as a Table Sugar Replacement in High-Sugar Breakfasts.","Effects of Fresh Mango as a Table Sugar Replacement on Postprandial Intestinal Permeability and Inflammation Following a High-Sugar Breakfast.","Inclusion Criteria:\n\n* 18 - 45 years.\n* Body mass index between 18.5-35.0 kg\u002Fm2\n* Not pregnant or expecting to become pregnant (females only)\n* Not postmenopausal (females only).\n* No known chronic medical conditions (e.g., type 2 diabetes, cardiovascular disease, inflammatory diseases, etc.)\n* No history of using tobacco\u002Fillicit drugs\n* No history of using glucose-lowering medications\u002Fsupplements.\n* No history of using prescribed anti-inflammatory medications\n* Does not use over-the-counter anti-inflammatory medications ≥2x\u002Fweek\n* Does not have a pacemaker.\n* No relevant food allergies\u002Fintolerances\n* Able to lay supine for at least ten minutes.\n\nExclusion Criteria:\n\n* Not between the ages of 18-45\n* Body mass index \\\u003C 18.5 kg\u002Fm2 or \\>35.0 kg\u002Fm2\n* Pregnant (females only)\n* Postmenopausal status (females only).\n* Been diagnosed with a chronic medical conditions (e.g., type 2 diabetes, cardiovascular disease, inflammatory diseases, etc.)\n* Uses tobacco products or any illicit drugs.\n* Uses glucose-lowering drugs\u002Fsupplements.\n* Regularly takes anti-inflammatory drugs (more than 2x week).\n* Have a pacemaker.\n* Allergic to mango, wheat, gluten, and\u002For milk.\n* Unable to lay in supine position in the dark for at least ten minutes.","45 Years",{"count":423,"type":22},35,[59],"Systemic inflammation and intestinal hyperpermeability (disruption of the gut barrier which allows nutrient molecules and bacteria to enter the bloodstream) are triggered by consumption of high-sugar meals and are linked to future development of cardiovascular disease (CVD). Previous research indicates that fresh mangos have properties that have positive effects on the intestinal barrier and local gut inflammation. The investigators want to understand if replacing table sugar (sucrose) with sugar from fresh mango (which also contains fiber and plant bioactives) will lead to decreased inflammatory and permeability biomarkers after eating a high-sugar breakfast. The investigators will compare the postprandial (post meal) levels of inflammatory (IL-6) and permeability (LPS, lipid binding protein (LBP), and soluble CD14) biomarkers in blood from participants who have consumed a meal sweetened with either sucrose or fresh mango.",[28],[428,429,430],"fresh mango","inflammation","intestinal permeability",{"date":177,"type":37},{"date":433,"type":37},"2026-02-01",{"date":435,"type":22},"2027-01",{"name":437,"class":72},"Ball State University",{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":445,"targetDuration":4,"studyType":23,"phases":447,"briefSummary":448,"conditions":449,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":73},"100642166","phase-1-a-single-and-multiple-ascending-dose-study-to-evaluate-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-syh2072-tablets-100642166","NCT07647783","A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 Tablets","A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2072 Tablets in Healthy Participants","Inclusion Criteria:\n\n1. Participants must be fully informed about the study content, procedures, and potential adverse reactions, and voluntarily sign the written informed consent form (ICF) before the study;\n2. Sex: Male or female;\n3. Age: 18-55 years old (inclusive);\n4. Body mass index in the range of 19 to 30 kg•m-2 \\[Body Mass Index (BMI) = weight\u002Fheight2 (kg•m\\^2)\\] (inclusive), with a body weight of no less than 50 kg for males (inclusive) and no less than 45 kg for females (inclusive);\n5. Participants are able to communicate well with the investigator and are able to complete the study in accordance with the protocol.\n\nExclusion Criteria:\n\n1. History of severe allergic diseases or allergic constitution (allergy to ≥ 3 drugs or foods);\n2. Use of corticosteroid drugs within 3 months prior to screening;\n3. Past and\u002For current clinically significant medical conditions, including but not limited to diseases of the circulatory, hematologic or hematopoietic, respiratory, endocrine, urinary, digestive, nervous or psychiatric systems, infections, tumors, severe trauma, or any other disease that the investigator considers should be excluded or may interfere with the interpretation of the study results;\n4. Postural tachycardia (heart rate increase \\> 30 beats\u002Fminute upon standing) or postural hypotension (decrease in SBP ≥ 20mmHg or DBP ≥ 10mmHg upon standing) at screening;\n5. Have undergone major surgery within 6 months prior to screening, or plan to undergo major surgery during the study;\n6. Potassium ion level outside the normal range in clinical chemistry tests at screening, or serum creatinine \\> upper limit of normal (ULN);\n7. Any one of the following at screening: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) \\> 1.2×ULN (one re-test within 1 week is allowed);\n8. Estimated glomerular filtration rate (eGFR) \\\u003C 90mL\u002Fmin\u002F1.73 m2 at screening;\n9. Prolonged QT\u002FQTc interval at screening (QTcF ≥ 450ms for males, ≥ 470ms for females);\n10. Positive for any of the following: HBsAg, HCV antibody, syphilis antibody, or HIV antibody;\n11. Blood loss or blood donation exceeding 200mL within 3 months prior to screening (excluding menstruation for females), and\u002For platelet donation within 2 weeks;\n12. Use of any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or dietary supplements (including vitamins, health products, etc.) within 28 days prior to screening;\n13. History of drug abuse, and\u002For use of illicit drugs within 3 months prior to screening, and\u002For habitual use of any psychotropic drugs, including Chinese herbal medicines, and\u002For a positive urine drug screen;\n14. Average daily smoking of more than 5 cigarettes (or an equivalent amount of tobacco in e-cigarettes) within 3 months prior to screening, and\u002For unwilling to avoid using any tobacco products during the study;\n15. Regular alcohol consumption within 6 months prior to screening, defined as more than 14 units of alcohol per week (1 unit = 360mL of 5% alcohol beer or 45mL of 40% alcohol spirits or 150mL of 12% alcohol wine), and\u002For inability to abstain from alcohol intake during the study, and\u002For a positive breath alcohol test;\n16. Excessive daily consumption of tea, coffee, and\u002For caffeinated beverages (8 cups or more, 1 cup = 250mL) within 1 month prior to screening, and\u002For unwilling to abstain from tea, coffee, and\u002For caffeinated foods, grapefruit and\u002For grapefruit juice, and\u002For poppy-containing products during the study;\n17. Having a fertility plan (including sperm or egg donation) from the time of signing the ICF until 3 months after the last dose, and\u002For unwilling to use an effective non-drug method of contraception;\n18. Participation in any clinical study within 3 months prior to screening;\n19. Participants who may be unable to complete the study for other reasons or who are deemed unsuitable for inclusion by the investigator.\n\n    In addition to the above requirements, female participants who meet the following criteria will also be excluded:\n20. Pregnant or lactating women;\n21. Use of oral contraceptives within 28 days prior to screening;\n22. Use of long-acting estrogen and\u002For progestogen injections and\u002For implants within 6 months prior to screening; 23）Women of childbearing potential who have had unprotected sexual intercourse with a partner within 28 days prior to dosing.",{"count":446,"type":22},112,[25],"This is a first-in-human study to evaluate the safety, tolerability, PK, and PD characteristics of SYH2072 Tablets after single and multiple oral doses in healthy participants.",[28],"2026-06-09",{"date":323,"type":37},{"date":453,"type":37},"2026-01-15",{"date":455,"type":22},"2027-04-01",{"name":457,"class":44},"InnovStone Therapeutics Limited",{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":189,"enrollmentInfo":465,"targetDuration":4,"studyType":23,"phases":467,"briefSummary":468,"conditions":469,"keywords":470,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":479},"100632247","phase-1-a-study-to-investigate-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-azd1043-in-healthy-adult-participants-living-with-overweight-andor-obesity-100632247","NCT07511205","A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and\u002For Obesity.","A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1043 Following Single and Multiple Ascending Doses Via Subcutaneous and\u002For Intravenous Administration in Healthy Adult Participants Living With Overweight and\u002For Obesity.","Inclusion Criteria:\n\n* All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.\n* Females of non-childbearing potential must be confirmed as postmenopausal or have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.\n* Have a body mass index between 25 and 39.9 kg\u002Fm2 (Global cohorts \\[Parts A1 and B1\\]), or 23 and 39.9 kg\u002Fm2 (Japanese \\[Parts A2 and B2\\] and Chinese \\[Part A3\\] cohorts) inclusive and weigh at least 50 kg.\n* For the Parts A2 and B2, participants should be Japanese (natives of Japan or Japanese Americans), having both parents and 4 grandparents who are Japanese. This includes healthy second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan.\n* For the Part A3, participants should be Chinese defined as having both parents and 4 grandparents who are ethnically Chinese. This includes second and third generation Chinese whose parents or grandparents are living in a country other than China.\n\nExclusion Criteria:\n\n* History of any clinically important disease or disorder.\n* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Any clinically important illness, medical\u002Fsurgical procedure, or trauma within 4 weeks of the first administration of study intervention.\n* Any clinically important abnormalities in laboratory values, clinical chemistry, hematology, urinalysis results, or vital signs.\n* History of severe allergy\u002Fhypersensitivity or ongoing clinically important allergy\u002Fhypersensitivity to drugs of a similar class to AZD1043.\n* Has received prescription, non-prescription, or experimental medications for weight loss within 3 months prior to the Screening Visit.\n* History of psychosis or bipolar disorder or major depressive disorder within the past 2 years with the participant being clinically unstable.",{"count":466,"type":22},104,[25],"The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and\u002For obesity, including participants of Japanese and Chinese descent.",[28,382],[471,115,116,90,472],"First time in human","Pharmacodynamics",{"date":326,"type":37},{"date":475,"type":37},"2026-03-30",{"date":477,"type":22},"2027-11-17",{"name":43,"class":44},3,{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":484,"acronym":485,"eligibilityCriteria":486,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":487,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":489,"briefSummary":490,"conditions":491,"keywords":493,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":504,"leadSponsor":506,"locationsCount":73},"100631253","location--and-frequency-dependent-effects-of-thalamic-temporal-interference-stimulation-during-sleep-100631253","NCT07498270","Location- and Frequency-Dependent Effects of Thalamic Temporal Interference Stimulation During Sleep","CAP-TI","Inclusion Criteria:\n\n* Medically healthy (based on self-report and study team review)\n* U.S. citizen or holding permanent resident status\n* English-speaking (able to provide consent and complete questionnaires)\n\nExclusion Criteria:\n\n* Any current or past history of neurological disorders or acquired neurological disease (e.g. stroke, traumatic brain injury), including intracranial lesions (including clinically significant findings identified in first MRI)\n* History of inpatient psychiatric hospitalization\n* History of head trauma resulting in prolonged loss of consciousness; or a history of greater than 3 grade I concussions\n* Current history of poorly controlled headaches including intractable or poorly controlled migraines\n* Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy except for a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Possible pregnancy or plan to become pregnant in the next 6 months (self reported)\n* Any metal in the head\n* Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator)\n* Dental implants\n* Permanent retainers\n* Any hair braid, dreadlocks, hair pieces, or extensions which cannot be taken out before the study sessions\n* Any head coverings or headdress that participant feels uncomfortable removing for the purposes of study sessions\n* Any medication that may alter seizure threshold taken during the study i.e., ADHD stimulants (Adderall, amphetamine); Tricyclic\u002Fatypical antidepressants (amitriptyline, doxepine, imipramine, maprotiline, nortriptyline, bupropion); SSRIs (Escitalopram, Fluoxetine, Sertraline); Antipsychotics (chlorpromazine, clozapine), Bronchodilators (theophylline, aminophylline); Antibiotics (fluoroquinolones, imipenem, penicillin, cephalosporins, metronidazole, isoniazid); Antivirals (valacyclovir, ritonavir); OTC antihistamines (diphenhydramine, Benadryl)\n* Claustrophobia (a fear of small or closed places)\n* Back problems that would prevent lying flat for up to two hours\n* Regular night-shift work (second or third shift)\n* Sleep apnea or other sleep disorder (self-reported)","40 Years",{"count":289,"type":22},[59],"This study is to find out whether a type of non-invasive electrical brain stimulation called temporal interference transcranial electrical stimulation (TI-TES) can temporarily change brain activity during sleep, especially sleep spindles (brain rhythms in the \\~8-16 Hz range). Up to 24 healthy participants in Dane County, Wisconsin will be enrolled for 3 overnight study visits. Participants can expect to be on study for approximately 5 weeks, depending on scheduling availability.",[492,28],"Healthy Adult Participants",[494,495,496,497,498,499,500,501],"sleep","spindles","non-rapid eye movement","SSD","neurobiology","impairment","brain stimulation","non-invasive stimulation",{"date":326,"type":37},{"date":343,"type":37},{"date":505,"type":22},"2028-02",{"name":507,"class":72},"University of Wisconsin, Madison",{"id":509,"slug":4,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":421,"enrollmentInfo":514,"targetDuration":4,"studyType":23,"phases":515,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":273,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":73},"100643500","NCT07643272","A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules","An Open-Label, Randomized, Four-Period, Six-Sequence Phase I Study to Evaluate the Effect of Food and Proton Pump Inhibitor Rabeprazole on the Pharmacokinetics of HMPL-760 Capsules in Healthy Participants","Inclusion Criteria:\n\n1. Participants are fully aware of this study and voluntarily sign the ICF.\n2. Male or female aged 18 to 45 years old (inclusive).\n3. Participant's body mass index (BMI) at screening: 18 kg\u002Fm2 \\\u003C BMI ≤ 29.9 kg\u002Fm2 and weight ≥ 50 kg for males and ≥ 45 kg for females.\n4. Participant is willing and able to comply with the protocol in all aspects.\n\nExclusion Criteria:\n\n1. Known history of any gastrointestinal surgery or any condition that could affect drug absorption (e.g., cholecystectomy, achlorhydria, peptic ulcer disease, gastric\u002Fintestinal surgery or history of resection; prior appendectomy or hernia repair is allowed).\n2. Clinically significant disease within 8 weeks prior to the first dose or clinically significant infection within 4 weeks prior to the first dose.\n3. Clinically significant abnormal findings in physical examination, vital signs, or laboratory tests at screening.\n4. Systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\> 90 mmHg at screening.\n5. Participants who smoked over 10 cigarettes daily within 3 months before screening.",{"count":289,"type":22},[25],"This is a single-center, open-label, randomized, four-period, six-sequence study with a planned enrollment of 24 healthy participants. The study consists of a screening period, a dosing period (Cycles 1, 2, 3, and 4), and a follow-up period. Screening must occur within 14 days prior to the first dose of study drug. Enrolled participants will be randomly assigned to one of 6 dosing sequences in the ratio of 1:1:1:1:1:1 to complete Cycles 1-3 dosing to evaluate the effect of different types of food on the PK of HMPL-760, and then to receive rabeprazole and HMPL-760 in Cycle 4 to assess the effect of PPI on the PK of HMPL-760 (see dosing sequence table for details).",[28],"2026-06-08",{"date":407,"type":37},{"date":521,"type":22},"2026-06",{"date":523,"type":22},"2026-12",{"name":525,"class":44},"Hutchmed",{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":533,"targetDuration":4,"studyType":23,"phases":535,"briefSummary":536,"conditions":537,"keywords":538,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":547,"locationsCount":73},"100632429","phase-1-a-study-to-assess-the-effect-of-azd0780-on-the-pharmacokinetics-of-azd4954-and-vice-versa-in-healthy-adults-100632429","NCT07513571","A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults","An Open-label Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults.","Inclusion Criteria:\n\n* All females must have a negative pregnancy test at the Screening Visit.\n* Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception.\n* Females of non-childbearing potential must be confirmed as postmenopausal or have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation or tubal occlusion.\n* Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods.\n* Have a body mass index between 18 and 35 kg\u002Fm2 inclusive and weigh at least 50 kg.\n\nExclusion Criteria:\n\n* History of any clinically important disease or disorder.\n* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Any clinically important illness, medical\u002Fsurgical procedure, or trauma within 4 weeks of the first administration of study intervention.\n* Participants with known bleeding or coagulation disorders.\n* Any clinically important abnormalities in laboratory values, clinical chemistry, hematology, urinalysis results, or vital signs.\n* Any positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).\n* Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead electrocardiogram at screening.\n* Participants who are current smokers or have used any tobacco or nicotine-containing products (including e-cigarettes) within 3 months prior to screening; known or suspected history of alcohol or drug abuse; positive screen for drugs of abuse, alcohol, or cotinine at screening or on each admission to the Clinical Unit.\n* History of severe allergy\u002Fhypersensitivity or ongoing clinically important allergy\u002Fhypersensitivity or history of hypersensitivity to drugs of a similar chemical structure or class to AZD4954 or laroprovstat.\n* Participants who have previously received AZD4954.\n* Treatment with any lipid-lowering therapy or laroprovstat within the 3 months prior to the Screening Visit.",{"count":534,"type":22},32,[25],"The purpose this study is to measure the impact of laroprovstat (AZD0780) on the pharmacokinetics (PK) of AZD4954 and the impact of AZD4954 on the PK of laroprovstat in healthy male and female participants.",[28],[90,539,540,541,542],"Drug-drug interaction","Dyslipidemias","Hypercholesterolemia","Lipoprotein (a)",{"date":450,"type":37},{"date":545,"type":37},"2026-04-10",{"date":64,"type":22},{"name":43,"class":44},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":374,"enrollmentInfo":555,"targetDuration":4,"studyType":23,"phases":557,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":273,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":73},"100598420","study-of-the-correlation-between-cortical-excitability-and-cytoarchitectonics-of-prefrontal-cortex-in-healthy-adult-participants-using-transcranial-magnetic-stimulation-coupled-to-eeg-and-high-field-mri-100598420","NCT07071259","Study of the Correlation Between Cortical Excitability and Cytoarchitectonics of Prefrontal Cortex in Healthy Adult Participants, Using Transcranial Magnetic Stimulation Coupled to EEG and High-field MRI","FrontalProbe","Inclusion Criteria:\n\n* People aged 18 to 35\n* People affiliated with a social security scheme or beneficiary of such a scheme\n* People who have signed the informed consent\n* Right-handed people\n* People with a body mass index between 18 and 26\n* People able to abstain from alcohol for 24 hours prior to the experiment\n* People able to remain perfectly still for 15 minutes straight, and able to have reduced mobility for 3 hours\n* People able to of not using narcotics (marijuana, cocaine, ecstasy, MDMA, ketamine, etc.) during the 15 days preceeding the experiment.\n* Conducting a pregnancy test before inclusion for women of childbearing age and when the research is conducted over a long period, at a frequency adapted to the gaze of the research acts\n* Effective contraception for women of childbearing potential\n\nExclusion Criteria:\n\n* Pregnant, parturient, or breastfeeding\n* Protected adults\n* Minors\n* People staying in a healthcare or social institution\n* People in an emergency situation\n* People deprived of their liberty\n* People with the usual contraindications to MRI\n\n  * Ferromagnetic surgical clips, ocular implants, metallic foreign bodies intraocularly or in the nervous system, implants or metallic objects susceptible to concentrate the radio frequency field, cochlear implants, brain stimulator or cardiac pacemaker, presence of a craniotomy scar, agitation\n  * Claustrophobia\n  * Large, black tattoo close to the orofacial area\n* People not wishing to be informed of abnormalities discovered at the MRI\n* People with a history of epilepsy or suffering from epilepsy\n* Individuals whose parents, children, siblings, or parents have a history of epilepsy\n* People with known neurological and\u002For psychiatric disorders with past and\u002For current medical treatment, or drug addiction\n* Staff with a hierarchical link to the investigators",{"count":556,"type":22},34,[59],"Repeated transcranial magnetic stimulation (rTMS) is mainly used to treat mood disorders by addressing differences in brain function, particularly in the dorsolateral prefrontal cortex (DLPFC), which affects emotions and executive functions. The therapy aims to enhance the left DLPFC or suppress the right. It has been approved for severe major depression in several countries (Canada and Israel since 2002, USA since 2008) and is in the process of being validated in Europe but is not yet reimbursed in France. due to variable results from one study to another and lack of standardization issues.\n\nIn a previous study, by recording electroencephalographic (EEG) rhythms before and after rTMS treatment of the DLPFC, the investigators showed on a small cohort of patients (n=17) with major or bipolar depression, that the responder patients showed higher EEG theta rhythms in the DLPFC but also and especially in parietal regions. This suggests that the DLPFC is part of the fronto-parietal central executive network (CEN), which is important for working memory and cognitive control. The CEN is not well connected in severe resistant depression, possibly leading to negative emotional bias. The rTMS cure of DLPFC can be interpreted as improving depressive symptoms through the normalization of the CEN by increasing DLPFC excitability and its downward connectivity. However experimental and clinical evidence for this mechanism, among others, is still to be demonstrated, and remission rates of rTMS from DLPFC in drug-resistant depression are still low (20-40%).\n\nTo improve these response rates to rTMS in DLPFC, it is essential to continue research aimed at improving clinical practices through a better knowledge of the functional neuroanatomy and mechanisms of action of rTMS. This will require the definition of biomarkers allowing in particular to better target the DLPFC, this structure beeing indeed relatively poorly defined on the neuroanatomical level (large portion of the medial frontal gyrus). To this end, the investigators have set up a collaborative research program with Dr. Corey Keller, psychiatrist at Stanford University USA, which was jointly funded in 2022 by the Agence Nationale pour la Recherche (ANR) and the National Institute of Health (NIH) - FrontalProbe project \"Probing the dorsolateral prefrontal cortex and central executive network for improving neuromodulation in depression\". The ultimate aim of this project is to develop and test different strategies for targeting the DLPFC in the rTMS treatment of pharmaco-resistant depressive patients, following the fundamental neuroanatomical and pathophysiological hypothesis that patients will respond better to therapy if their CEN network is better modulated. This clinical trial will take place in Stanford, USA, in the years 2025-2026. Previously, the investigators are working on the development of methodological strategies aimed at preferentially activating, in a personalized way, the part of the DLPFC that projects onto the PPC. This is the subject of the present protocol, which aims to identify this subpart of the DLPFC to be targeted as a priority for modulating the CEN, through neuroanatomical measurements with high-field MRI and cortical excitability by TMS-EEG in healthy subjects. To this end, the investigators will use a small cohort of healthy subjects who will have one multimodal MRI acquisition session of at 7T and one TMS-EEG session. The 7T MRI data, acquired at the Centre de Résonance Magnétique en Biologie et Médecine (CRMBM), will be used to obtain anatomical markers of the DLPFC. TMS-EEG data, acquired at the Institut de Neurosciences de Systèmes (INS), will be used for cortical excitability measurements of the DLPFC and its projection sites, notably the PPC. At this stage, no data exchange is planned with our American partners.\n\nFirstly, the processing of MRI data will include segmentation of gray and white matter, reconstruction of the cortical surface and estimation of the different cortical layers, mainly by monitoring variations in the T1 parameter along the cortical mantle. Other MRI parameters will also be acquired to maximize the specificity of the segmentation of the DLPFC into sub-regions, firstly by identifying the part of the DLPFC that connects preferentially to the PPC using the reconstruction of fiber bundles from diffusion MRI and functional resting MRI. Secondly, during TMS-EEG acquisitions, participants will be stimulated in 3 sub-regions of the DLPFC. For each target, the analyses of the EEG data will focus on quantifying connectivity with the PPC as well as their spectral signature, which is possibly an indirect reflection of the neuronal composition of the stimulated regions.\n\nCorrelation of 7T MRI and TMS-EEG data will help set optimal DLPFC targeting criteria for PPC activation. The aim is to create an MRI-based targeting procedure for clinical practice. In this sense, TMS-EEG will serve as validation of MRI markers.",[28,560,561,562,563,564],"Magnetic Stimulation","MRI","EEG","Dorsolateral Prefrontal Cortex","rTMS Stimulation","2026-06-03",{"date":343,"type":37},{"date":568,"type":22},"2026-07-15",{"date":570,"type":22},"2028-04",{"name":572,"class":573},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":575,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":576,"targetDuration":4,"studyType":23,"phases":577,"briefSummary":26,"conditions":578,"keywords":579,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":582,"completionDateStruct":583,"leadSponsor":584,"locationsCount":45},"100591438",{"count":21,"type":22},[25],[28,29],[31,32],"2026-06-02",{"date":565,"type":37},{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":189,"enrollmentInfo":592,"targetDuration":4,"studyType":23,"phases":594,"briefSummary":595,"conditions":596,"keywords":4,"overallStatus":273,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":4},"100637630","phase-1-a-study-to-evaluate-safety-tolerability-and-pharmacokinetics-of-enicepatide-in-generally-healthy-adult-chinese-participants-100637630","NCT07626515","A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants","A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Enicepatide in Adult Chinese Participants With Body Mass Index ≥23.0 kg\u002Fm2","Inclusion Criteria:\n\n* No evidence of active or chronic disease as determined by detailed medical and surgical history and the results of a physical examination, vital signs, 12 lead electrocardiogram (ECG), or clinical laboratory tests\n* BMI ≥23 kg\u002Fm\\^2 at screening\n* Agreement to adhere to the contraception requirements\n\nExclusion Criteria:\n\n* History of acute or chronic pancreatitis\n* History of clinically significant gallbladder disease in the opinion of the investigator\n* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder\n* History or presence of an abnormal ECG that is deemed clinically significant in the opinion of the investigator\n* Clinically significant abnormalities (as judged by the investigator) in laboratory test results\n* History or presence of clinically significant cardiovascular disease, renal disease, hepatic disease, gastrointestinal disease, hematological disease, immunological disease, neurological disease, endocrine disease, metabolic disease, pulmonary disease, or history of any of these diseases with renal, hepatic, or cardiopulmonary dysfunction",{"count":593,"type":22},36,[25],"This is a Phase I, randomized, double-blinded, placebo-controlled, study to assess the safety, tolerability, and pharmacokinetics (PK) of enicepatide in generally healthy adult Chinese participants with body mass index (BMI) ≥23.0 kilograms per meter squared (kg\u002Fm\\^2).",[28],"2026-06-01",{"date":599,"type":37},"2026-06-04",{"date":601,"type":22},"2026-06-26",{"date":603,"type":22},"2027-05-30",{"name":605,"class":44},"Hoffmann-La Roche"]